Inventor
YAT SUN OR
Inventor
US
Overview
Patents· 65 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds35%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
A61KPreparations for medical, dental or toiletry purposes25%
C07BGeneral methods of organic chemistry3%
C07CAcyclic or carbocyclic compounds3%
C07JSteroids2%
C07KPeptides2%
Y02ATechnologies for adaptation to climate change2%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%
PatentTitleYear
12,570,663Crystal forms of an anti-sars CoV-2 agent202612,552,777Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof202612,540,141Spiropyrrolidine derived antiviral agents202612,509,470Antiviral heterocyclic compounds202512,496,282Hepatitis B antiviral agents202512,479,854Spiropyrrolidine derived antiviral agents202512,459,923Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof202512,398,147Macrocyclic spiropyrrolidine derived antiviral agents202512,384,75317-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof202512,358,921Antiviral heterocyclic compounds202512,297,209Benzodiazepine derivatives as RSV inhibitors202512,281,140Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof202512,268,694Combination pharmaceutical agents as RSV inhibitors202512,264,159Functionalized heterocycles as antiviral agents202512,162,857Antiviral compounds202412,157,731EIF4E inhibitors and uses thereof202412,145,941Heterocyclic antiviral agents202412,145,942Spiropyrrolidine derived antiviral agents202412,054,493Hepatitis B antiviral agents202412,018,017Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof202412,011,425Hepatitis B antiviral agents202412,006,326Antiviral heterocyclic compounds202412,006,291Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid202411,993,600Saturated spirocyclics as antiviral agents202411,976,084Spiropyrrolidine derived antiviral agents202411,970,502Macrocyclic antiviral agents202411,958,879Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof202411,952,389Benzodiazepine derivatives as RSV inhibitors202411,945,824Heterocyclic compounds as anti-viral agents202411,945,830Antiviral heterocyclic compounds202411,919,910Spiropyrrolidine derived antiviral agents202411,912,714Spiropyrrolidine derived antiviral agents202411,912,695Benzodiazepine derivatives as RSV inhibitors202411,891,393Functionalized heterocycles as antiviral agents202411,858,945Alkyne-containing antiviral agents202411,834,436Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof202311,802,125Functionalized heterocyclic compounds as antiviral agents202311,760,755Hepatitis B antiviral agents202311,753,403EIF4E inhibitors and uses thereof202311,738,019Substituted heterocycles as antiviral agents202311,718,641Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof202311,596,611Hepatitis B antiviral agents202311,578,097Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof202311,572,367Antiviral heterocyclic compounds202311,560,368Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof202311,555,032Isoxazole derivatives as FXR agonists and methods of use thereof202311,534,439Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors202211,505,558Antiviral heterocyclic compounds202211,472,808Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents202211,466,033Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors202211,420,976Heterocyclic compounds as anti-viral agents202211,390,631Benzodiazepine derivatives as RSV inhibitors202211,384,090Spiropyrrolidine derived antiviral agents202211,377,450Functionalized heterocycles as antiviral agents202211,358,953Functionalized peptides as antiviral agents202211,352,363Spiropyrrolidine derived antiviral agents202211,345,699Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof202211,339,170Spiropyrrolidine derived antiviral agents202211,325,916Spiropyrrolidine derived antiviral agents202211,319,325Macrocyclic spiropyrrolidine derived antiviral agents202211,254,664Benzodiazepine derivatives as RSV inhibitors202211,236,111Hepatitis B antiviral agents202211,236,108Functionalized heterocycles as antiviral agents202211,198,693Functionalized heterocycles as antiviral agents202111,179,400Heterocyclic compounds as RSV inhibitors2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to ENANTA PHARM INC (63)· patent assignee history
2021–2026Based in US· patent location history
2023–2024Patents assigned to PIC THERAPEUTICS INC (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ENANTA PHARM INC | 63 | 2021–2026 |
| PIC THERAPEUTICS INC | 2 | 2023–2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 65 | 2021–2026 |